ZA200400165B - A composition and uses therefor for combating hangover. - Google Patents

A composition and uses therefor for combating hangover. Download PDF

Info

Publication number: ZA200400165B
Authority: ZA; South Africa
Prior art keywords: composition; fructose; containing oligosaccharide; branched chain; chain amino
Prior art date: 2001-07-10

Application number

ZA200400165A

Other languages

English (en)

Inventor

Neil Roland Mcgregor

Original Assignee

Penam Invest Pty Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-07-10

Filing date

2004-01-09

Publication date

2004-11-01

2004-01-09 Application filed by Penam Invest Pty Ltd filed Critical Penam Invest Pty Ltd

2004-11-01 Publication of ZA200400165B publication Critical patent/ZA200400165B/en

Links

239000000203 mixture Substances 0.000 title claims abstract description 56
206010019133 Hangover Diseases 0.000 title description 13
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 112
229920001542 oligosaccharide Polymers 0.000 claims abstract description 43
150000002482 oligosaccharides Chemical class 0.000 claims abstract description 43
229930091371 Fructose Natural products 0.000 claims abstract description 34
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims abstract description 34
239000005715 Fructose Substances 0.000 claims abstract description 34
208000024891 symptom Diseases 0.000 claims abstract description 30
238000011282 treatment Methods 0.000 claims abstract description 24
238000011321 prophylaxis Methods 0.000 claims abstract description 22
150000005693 branched-chain amino acids Chemical class 0.000 claims description 23
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 22
239000008103 glucose Substances 0.000 claims description 21
231100000167 toxic agent Toxicity 0.000 claims description 21
239000003440 toxic substance Substances 0.000 claims description 21
229940088594 vitamin Drugs 0.000 claims description 14
229930003231 vitamin Natural products 0.000 claims description 14
235000013343 vitamin Nutrition 0.000 claims description 14
239000011782 vitamin Substances 0.000 claims description 14
150000003722 vitamin derivatives Chemical class 0.000 claims description 13
AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 claims description 11
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 10
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 10
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 7
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 6
239000003814 drug Substances 0.000 claims description 6
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 5
229960002685 biotin Drugs 0.000 claims description 5
235000020958 biotin Nutrition 0.000 claims description 5
239000011616 biotin Substances 0.000 claims description 5
229960000310 isoleucine Drugs 0.000 claims description 5
238000004519 manufacturing process Methods 0.000 claims description 5
GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 3
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 3
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 3
229940014662 pantothenate Drugs 0.000 claims description 3
235000019161 pantothenic acid Nutrition 0.000 claims description 3
239000011713 pantothenic acid Substances 0.000 claims description 3
239000004474 valine Substances 0.000 claims description 3
239000002253 acid Substances 0.000 claims 1
229960001031 glucose Drugs 0.000 description 15
150000001875 compounds Chemical class 0.000 description 11
238000000034 method Methods 0.000 description 9
IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 8
239000004480 active ingredient Substances 0.000 description 6
238000002360 preparation method Methods 0.000 description 6
230000009471 action Effects 0.000 description 5
230000037396 body weight Effects 0.000 description 5
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 4
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 4
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 4
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 4
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 4
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
239000002775 capsule Substances 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 4
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
229960003136 leucine Drugs 0.000 description 4
239000000047 product Substances 0.000 description 4
239000000243 solution Substances 0.000 description 4
239000006188 syrup Substances 0.000 description 4
235000020357 syrup Nutrition 0.000 description 4
239000003826 tablet Substances 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
-1 troches Substances 0.000 description 4
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
229930006000 Sucrose Natural products 0.000 description 3
240000008042 Zea mays Species 0.000 description 3
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 3
235000002017 Zea mays subsp mays Nutrition 0.000 description 3
239000011149 active material Substances 0.000 description 3
230000004075 alteration Effects 0.000 description 3
238000000576 coating method Methods 0.000 description 3
235000005822 corn Nutrition 0.000 description 3
230000035622 drinking Effects 0.000 description 3
239000003937 drug carrier Substances 0.000 description 3
239000000796 flavoring agent Substances 0.000 description 3
235000008216 herbs Nutrition 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
239000000463 material Substances 0.000 description 3
230000004060 metabolic process Effects 0.000 description 3
230000004048 modification Effects 0.000 description 3
238000012986 modification Methods 0.000 description 3
239000000843 powder Substances 0.000 description 3
239000002904 solvent Substances 0.000 description 3
239000005720 sucrose Substances 0.000 description 3
229960004295 valine Drugs 0.000 description 3
SPFMQWBKVUQXJV-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;hydrate Chemical compound O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O SPFMQWBKVUQXJV-BTVCFUMJSA-N 0.000 description 2
241000167854 Bourreria succulenta Species 0.000 description 2
229920002261 Corn starch Polymers 0.000 description 2
AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 2
QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 2
ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
235000002414 D-alpha-tocopherylacetate Nutrition 0.000 description 2
239000011740 D-alpha-tocopherylacetate Substances 0.000 description 2
PMVSDNDAUGGCCE-TYYBGVCCSA-L Ferrous fumarate Chemical compound [Fe+2].[O-]C(=O)\C=C\C([O-])=O PMVSDNDAUGGCCE-TYYBGVCCSA-L 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
102000004877 Insulin Human genes 0.000 description 2
108090001061 Insulin Proteins 0.000 description 2
QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 2
CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 2
235000019766 L-Lysine Nutrition 0.000 description 2
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 2
239000004158 L-cystine Substances 0.000 description 2
235000019393 L-cystine Nutrition 0.000 description 2
229930182844 L-isoleucine Natural products 0.000 description 2
239000004395 L-leucine Substances 0.000 description 2
235000019454 L-leucine Nutrition 0.000 description 2
229930182821 L-proline Natural products 0.000 description 2
239000004472 Lysine Substances 0.000 description 2
229920002774 Maltodextrin Polymers 0.000 description 2
239000005913 Maltodextrin Substances 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
FCASKLHVRFDIJB-UHFFFAOYSA-N Riboflavine Natural products Cc1cc2N=C3C(NC(=O)NC3=O)N(CC(O)C(O)C(O)CO)c2cc1C FCASKLHVRFDIJB-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
239000004473 Threonine Substances 0.000 description 2
QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
229960003767 alanine Drugs 0.000 description 2
OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
230000000844 anti-bacterial effect Effects 0.000 description 2
239000003429 antifungal agent Substances 0.000 description 2
229940121375 antifungal agent Drugs 0.000 description 2
229940085469 ascorbic acid 300 mg Drugs 0.000 description 2
229960001230 asparagine Drugs 0.000 description 2
229960005261 aspartic acid Drugs 0.000 description 2
235000013734 beta-carotene Nutrition 0.000 description 2
239000011648 beta-carotene Substances 0.000 description 2
TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 2
229960002747 betacarotene Drugs 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
235000019693 cherries Nutrition 0.000 description 2
230000001149 cognitive effect Effects 0.000 description 2
239000008120 corn starch Substances 0.000 description 2
229960002104 cyanocobalamin Drugs 0.000 description 2
235000000639 cyanocobalamin Nutrition 0.000 description 2
239000011666 cyanocobalamin Substances 0.000 description 2
229960003067 cystine Drugs 0.000 description 2
ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 2
229940039770 d-alpha-tocopheryl acetate Drugs 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
229960000673 dextrose monohydrate Drugs 0.000 description 2
239000002612 dispersion medium Substances 0.000 description 2
230000000694 effects Effects 0.000 description 2
230000004149 ethanol metabolism Effects 0.000 description 2
239000000284 extract Substances 0.000 description 2
235000002332 ferrous fumarate Nutrition 0.000 description 2
239000011773 ferrous fumarate Substances 0.000 description 2
229960000225 ferrous fumarate Drugs 0.000 description 2
235000019634 flavors Nutrition 0.000 description 2
235000003599 food sweetener Nutrition 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
229960002989 glutamic acid Drugs 0.000 description 2
230000036541 health Effects 0.000 description 2
229960002885 histidine Drugs 0.000 description 2
229940125396 insulin Drugs 0.000 description 2
239000007951 isotonicity adjuster Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
229960001983 magnesium aspartate Drugs 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
CRSJYWPXKKSOCQ-CBAPHJFVSA-L magnesium;(2s)-2-aminobutanedioate;hydron;tetrahydrate Chemical compound O.O.O.O.[Mg+2].[O-]C(=O)[C@@H](N)CC(O)=O.[O-]C(=O)[C@@H](N)CC(O)=O CRSJYWPXKKSOCQ-CBAPHJFVSA-L 0.000 description 2
229940035034 maltodextrin Drugs 0.000 description 2
244000005700 microbiome Species 0.000 description 2
150000002772 monosaccharides Chemical class 0.000 description 2
229960003966 nicotinamide Drugs 0.000 description 2
235000005152 nicotinamide Nutrition 0.000 description 2
239000011570 nicotinamide Substances 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
229960005190 phenylalanine Drugs 0.000 description 2
239000006187 pill Substances 0.000 description 2
229960002429 proline Drugs 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
229960002477 riboflavin Drugs 0.000 description 2
235000019192 riboflavin Nutrition 0.000 description 2
239000002151 riboflavin Substances 0.000 description 2
229960001153 serine Drugs 0.000 description 2
235000017557 sodium bicarbonate Nutrition 0.000 description 2
229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
239000001488 sodium phosphate Substances 0.000 description 2
229910000162 sodium phosphate Inorganic materials 0.000 description 2
239000000126 substance Substances 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
239000013589 supplement Substances 0.000 description 2
239000003765 sweetening agent Substances 0.000 description 2
229940078978 thiamine 2 mg Drugs 0.000 description 2
229960002898 threonine Drugs 0.000 description 2
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
229960004441 tyrosine Drugs 0.000 description 2
QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 2
235000005282 vitamin D3 Nutrition 0.000 description 2
239000011647 vitamin D3 Substances 0.000 description 2
229940021056 vitamin d3 Drugs 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
208000007848 Alcoholism Diseases 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
241000233866 Fungi Species 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
229930064664 L-arginine Natural products 0.000 description 1
235000014852 L-arginine Nutrition 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
229930195722 L-methionine Natural products 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
244000246386 Mentha pulegium Species 0.000 description 1
235000016257 Mentha pulegium Nutrition 0.000 description 1
235000004357 Mentha x piperita Nutrition 0.000 description 1
241000238367 Mya arenaria Species 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
206010039203 Road traffic accident Diseases 0.000 description 1
229920001800 Shellac Polymers 0.000 description 1
206010044565 Tremor Diseases 0.000 description 1
239000003070 absorption delaying agent Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
201000007930 alcohol dependence Diseases 0.000 description 1
230000001476 alcoholic effect Effects 0.000 description 1
108010081577 aldehyde dehydrogenase (NAD(P)+) Proteins 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
229940024606 amino acid Drugs 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
230000002686 anti-diuretic effect Effects 0.000 description 1
229940124538 antidiuretic agent Drugs 0.000 description 1
239000003160 antidiuretic agent Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
238000005842 biochemical reaction Methods 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000006189 buccal tablet Substances 0.000 description 1
FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
229960002079 calcium pantothenate Drugs 0.000 description 1
229940054665 calcium pantothenate 5 mg Drugs 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
150000003943 catecholamines Chemical class 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000007958 cherry flavor Substances 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000013329 compounding Methods 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000018044 dehydration Effects 0.000 description 1
238000006297 dehydration reaction Methods 0.000 description 1
239000003405 delayed action preparation Substances 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
230000002074 deregulated effect Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
150000002016 disaccharides Chemical class 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
238000000537 electroencephalography Methods 0.000 description 1
230000002124 endocrine Effects 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
206010016256 fatigue Diseases 0.000 description 1
235000013305 food Nutrition 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
230000002414 glycolytic effect Effects 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
235000019534 high fructose corn syrup Nutrition 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
235000001050 hortel pimenta Nutrition 0.000 description 1
230000004179 hypothalamic–pituitary–adrenal axis Effects 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
230000006698 induction Effects 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
239000008101 lactose Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
229960004452 methionine Drugs 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
230000008693 nausea Effects 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
239000007968 orange flavor Substances 0.000 description 1
230000037361 pathway Effects 0.000 description 1
230000036581 peripheral resistance Effects 0.000 description 1
229960003742 phenol Drugs 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
230000004043 responsiveness Effects 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
229940081974 saccharin Drugs 0.000 description 1
235000019204 saccharin Nutrition 0.000 description 1
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
239000004208 shellac Substances 0.000 description 1
ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
229940113147 shellac Drugs 0.000 description 1
235000013874 shellac Nutrition 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
125000000185 sucrose group Chemical group 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
229940033663 thimerosal Drugs 0.000 description 1
229960002663 thioctic acid Drugs 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
239000003053 toxin Substances 0.000 description 1
230000014616 translation Effects 0.000 description 1
238000001291 vacuum drying Methods 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
235000012431 wafers Nutrition 0.000 description 1
239000009637 wintergreen oil Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Addiction (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurosurgery (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Engineering & Computer Science (AREA)
Psychiatry (AREA)
Toxicology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Table Devices Or Equipment (AREA)
Dental Preparations (AREA)
Medicinal Preparation (AREA)

ZA200400165A 2001-07-10 2004-01-09 A composition and uses therefor for combating hangover. ZA200400165B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
AUPR6261A AUPR626101A0 (en)	2001-07-10	2001-07-10	A composition and uses therefor

Publications (1)

Publication Number	Publication Date
ZA200400165B true ZA200400165B (en)	2004-11-01

Family

ID=3830225

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200400165A ZA200400165B (en)	2001-07-10	2004-01-09	A composition and uses therefor for combating hangover.

Country Status (9)

Country	Link
US (1)	US7449448B2 (fr)
EP (1)	EP1411879B1 (fr)
JP (1)	JP2004534094A (fr)
AT (1)	ATE406903T1 (fr)
AU (2)	AUPR626101A0 (fr)
CA (1)	CA2453159A1 (fr)
DE (1)	DE60228722D1 (fr)
WO (1)	WO2003006073A1 (fr)
ZA (1)	ZA200400165B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20070034459A (ko) *	2004-02-17	2007-03-28	마르쿠스 그라프 폰 마투시카-그라이펜클라우	알콜 대사 조절 조성물
WO2007016954A1 (fr) *	2005-07-29	2007-02-15	Matuschka-Greiffenclau Markus	Composition réduisant les risques de cancer du sein induit par l’alcool ou les médicaments
WO2007016953A1 (fr) *	2005-07-29	2007-02-15	Matuschka-Greiffenclau Markus	Composition réduisant les risques de cancer du foie induit par l’alcool
WO2007016949A1 (fr) *	2005-07-29	2007-02-15	Matuschka-Greiffenclau Markus	Composition réduisant les risques de neuropathie induite par l’alcool
WO2007016951A1 (fr) *	2005-07-29	2007-02-15	Matuschka-Greiffenclau Markus	Composition réduisant les risques de cancer du pancréas induit par l’alcool
WO2007016950A1 (fr) *	2005-07-29	2007-02-15	Matuschka-Greiffenclau Markus	Composition réduisant les risques de maladie neurodégénérative induite par l’alcool
WO2007016952A1 (fr) *	2005-07-29	2007-02-15	Matuschka-Greiffenclau Markus	Composition réduisant les risques de cancer de l’oesophage ou de l’oropharyngolaryngée induit par l’alcool
SI1909600T1 (sl) *	2005-07-29	2012-07-31	Tima Foundation	Zmes za nadzor metabolizma alkohola in za zmanjšanje nevarnosti z alkoholom induciranih bolezni
JP5085329B2 (ja) *	2005-09-12	2012-11-28	協和発酵バイオ株式会社	α−リポ酸含有組成物
US8633192B2 (en)	2006-12-15	2014-01-21	Tima Foundation	Compositions and uses thereof
RU2358723C1 (ru) *	2008-01-31	2009-06-20	Андрей Александрович Иващенко	Средство, обладающее антипохмельным действием, биологически активная добавка, фармацевтическая композиция, лекарственное средство и способ получения
RU2396076C1 (ru) *	2009-01-29	2010-08-10	Андрей Александрович Иващенко	Средство, уменьшающее степень острой алкогольной интоксикации (опьянения) и обладающее антипохмельным действием, биологически активная добавка, фармацевтическая композиция, лекарственное средство и способ получения
US9474802B2 (en)	2010-10-28	2016-10-25	Jonathan Burg	Compositions and methods to reduce hangover and reduce blood alcohol levels after alcohol consumption
DE102011013224A1 (de)	2011-03-07	2012-09-13	Roman Gerdes	Orthomolekulares Mittel gegen die Folgen von Alkoholkonsum
HK1201693A1 (en)	2011-11-15	2015-09-11	Tima Foundation	Composition for protection against cell-damaging effects
WO2013136349A1 (fr) *	2012-03-14	2013-09-19	Biffi-Helps S.R.L.	Composé adjuvant de digestion
WO2015066799A1 (fr) *	2013-11-06	2015-05-14	Jarrouj Salim	Composition et procede pour accroitre la vitesse du metabolisme de l'alcool et prevenir les symptomes de la gueule de bois
US10413563B2 (en) *	2017-05-10	2019-09-17	Emerald Neuro-Recover, LLC	Neurochemical wellness program
WO2021125934A1 (fr) *	2019-12-18	2021-06-24	Unibiolabs Internacional S.A De C.V	Formulations destinées à être utilisées dans le traitement de différents types d'addictions et de dépendance à des substances actives

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4496548A (en) *	1983-02-04	1985-01-29	Moldowan Mervin J	Composition and method for reducing hangover
EP0185117A1 (fr)	1984-12-21	1986-06-25	IPEX Getränke-Herstellungs- und Vertriebsgesellschaft mbH	Boisson
RU2086237C1 (ru) *	1994-12-05	1997-08-10	Олег Николаевич Немировский	Средство для купирования алкогольного абстинентного синдрома
GB9526741D0 (en)	1995-12-30	1996-02-28	Sobering Thoughts Ltd	Product for combatting dehydration
FR2748935A1 (fr)	1996-05-23	1997-11-28	Clergeaud Jean	Solution buvable favorisant la baisse du taux d'alcoolemie
GB9725061D0 (en)	1997-11-27	1998-01-28	Tagg Npd Limited	Revitalisation formulation
RU2160589C1 (ru) *	2000-05-18	2000-12-20	Алекс Кашлинский	Средство для снижения алкогольного опьянения, предупреждения и снятия алкогольной интоксикации и похмельного синдрома и способ снижения алкогольного опьянения, предупреждения и снятия алкогольной интоксикации и похмельного синдрома с использованием этого средства

2001
- 2001-07-10 AU AUPR6261A patent/AUPR626101A0/en not_active Abandoned
2002
- 2002-07-05 AT AT02748426T patent/ATE406903T1/de not_active IP Right Cessation
- 2002-07-05 EP EP02748426A patent/EP1411879B1/fr not_active Expired - Lifetime
- 2002-07-05 US US10/483,393 patent/US7449448B2/en not_active Expired - Fee Related
- 2002-07-05 DE DE60228722T patent/DE60228722D1/de not_active Expired - Fee Related
- 2002-07-05 AU AU2002318969A patent/AU2002318969B2/en not_active Ceased
- 2002-07-05 WO PCT/AU2002/000890 patent/WO2003006073A1/fr not_active Ceased
- 2002-07-05 CA CA002453159A patent/CA2453159A1/fr not_active Abandoned
- 2002-07-05 JP JP2003511878A patent/JP2004534094A/ja not_active Withdrawn
2004
- 2004-01-09 ZA ZA200400165A patent/ZA200400165B/en unknown

Also Published As

Publication number	Publication date
EP1411879B1 (fr)	2008-09-03
DE60228722D1 (de)	2008-10-16
EP1411879A1 (fr)	2004-04-28
AU2002318969B2 (en)	2005-11-03
US7449448B2 (en)	2008-11-11
EP1411879A4 (fr)	2005-06-22
AUPR626101A0 (en)	2001-08-02
CA2453159A1 (fr)	2003-01-23
US20040248819A1 (en)	2004-12-09
WO2003006073A1 (fr)	2003-01-23
JP2004534094A (ja)	2004-11-11
ATE406903T1 (de)	2008-09-15

Publication	Publication Date	Title
EP1411879B1 (fr)	2008-09-03	Preparation et ses utilisations pour combattre la xylostomiase
AU2002318969A1 (en)	2003-05-22	A composition and uses therefor for combating hangover
US6031000A (en)	2000-02-29	Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use
EP0983726B1 (fr)	2006-10-25	Composition contenant des acides aminés et du tréhalose
CN103038356A (zh)	2013-04-10	乙酰半胱氨酸组合物及其使用方法
HUE032486T2 (en)	2018-05-02	An improved method for administering beta-hydroxy-beta-methylbutyrate (HMB)
US20050197398A1 (en)	2005-09-08	Therapeutic agent for hepatic disease
SK283853B6 (sk)	2004-03-02	Terapeutická/výživová kompozícia pre diabetikov
US4987123A (en)	1991-01-22	Compositions useful for the treatment and/or prevention of hepatic disorders, and their pharmaceutical use
CA2278854A1 (fr)	1998-08-13	Utilisation d'inhibiteurs des lipases gastro-intestinales (tetrahydrolipstatine) pour le traitement du diabete de tyse ii
US4898879A (en)	1990-02-06	Nurtitional composition for management of hepatic failure
EP0449787B1 (fr)	1995-09-27	Compositions pharmaceutiques, diététiques ou vétérinaires à activité eumétabolique
US6506552B2 (en)	2003-01-14	Amino acid-trehalose composition
JPH0420409B2 (fr)	1992-04-02
RU2372900C2 (ru)	2009-11-20	Ингибитор возникновения и развития рака печени для применения у пациентов-людей с циррозом печени, положительных по вирусу гепатита с
ZA200400123B (en)	2004-10-27	A composition for use in prophylaxis and/or treatment.
Tutelyan et al.	1990	The effect of aspartame on the activity of rat liver xenobiotic-metabolizing enzymes.
CZ297743B6 (cs)	2007-03-21	Pouzití acetyl-L-karnitinu ve spojení s biotinem k lécbe pacientu s diabetem mellitus typu 2 rezistentním na inzulín
US20250161270A1 (en)	2025-05-22	Pharmaceutical composition and medicament comprising l-tryptophan, l-5-hydroxytryptophan and a peripheral degradation inhibitor
US4716177A (en)	1987-12-29	Tolrestat for inhibition of weight gain
CN1739536A (zh)	2006-03-01	一种含甘草酸单钾盐的复合制剂及其制备方法与应用
AU2002344700A1 (en)	2003-01-29	A composition for use in prophylaxis and/or treatment
HK1026345B (en)	2007-04-13	Amino acid-trehalose composition